20/20 Biolabs, Inc. filed a Form S-1 registration statement for an initial public offering on 2025-12-12. It has amended it 2 times. As of its latest filing, on 2026-04-06, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.
What the filings say
Listing
Our common stock is listed on The Nasdaq Capital Market under the symbol “AIDX.” On April 2, 2026, the last reported sale price of our common stock on The Nasdaq Capital Market was $1.83.From the S-1 filed 2026-04-06
Use of proceeds
We currently expect to use the net proceeds that we receive from the exercise of the warrant for working capital and other general corporate purposes.From the S-1 filed 2026-04-06
Revenue
in the case of an issuer whose public float as calculated under paragraph (1) or (2) of this definition was zero or whose public float was less than $700 million, had annual revenues of less than $100 million during the most recently completed fiscal year for which audited financial statements are available.From the S-1 filed 2026-04-06
Net loss or income
As a result of the cumulative effect of the factors described above, we generated a net loss of $3,738,821 for the year ended December 31, 2025, as compared to $5,551,667 for the year ended December 31, 2024, a decrease of $1,812,846, or 32.65%.From the S-1 filed 2026-04-06
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2025-12-12 | Registration statement filed | S-1 |
| 2026-01-21 | Registration statement amended | S-1/A |
| 2026-01-26 | Registration statement amended | S-1/A |
| 2026-04-06 | Registration statement filed | S-1 |
Tools for this story
Each opens in a new tab, filled in for 20/20 Biolabs, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.